1.	Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
2.	Phase II/III Randomized Study of Fluorouracil, Cisplatin, and Radiotherapy Versus Gemcitabine Hydrochloride and Oxaliplatin in Patients With Unresectable, Nonmetastatic Cancer of the Biliary Tract Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
3.	Phase II/III Randomized Study of Adjuvant Therapy Comprising Gemcitabine Hydrochloride With Versus Without Cisplatin, Epirubicin Hydrochloride, and Fluorouracil Followed by Chemoradiotherapy With Fluorouracil or Capecitabine in Patients With Stage IB, II, or III Adenocarcinoma of the Pancreas Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SRSI-PACT-7, PACT-7, EU-20932, NCT00960284
4.	A Randomised Phase II/III Study of Cediranib (AZD2171) or Placebo in Combination With Cisplatin/Gemcitabine for Patients With Advanced Biliary Tract Cancers Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: ABC-03 09/0193, NCT00939848
5.	Phase II/III Randomized Study of Concurrent Cisplatin and Radiotherapy With Versus Without Induction Chemotherapy Comprising Gemcitabine Hydrochloride, Carboplatin, and Paclitaxel in Patients With Locally Advanced Nasopharyngeal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SINGAPORE-NCC0901, NCC0901, NCT00997906
6.	Phase III Randomized Study of Immediate Versus Deferred Adjuvant Chemotherapy After Radical Cystectomy in Patients With Stage III or IV Transitional Cell Carcinoma of the Bladder Urothelium Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: EORTC-30994, ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, NORDIC-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
7.	Phase III Randomized Study of Salvage Chemotherapy Comprising Dexamethasone, Cisplatin, and Gemcitabine Versus a Standard Platinum-Based Regimen (Dexamethasone, Cisplatin, and High-Dose Cytarabine) Before Autologous Stem Cell Transplantation and With or Without Maintenance Rituximab in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: CAN-NCIC-LY12, NCT00078949, LY12
8.	Phase III Randomized Study of Gemcitabine in Combination With Cisplatin Versus Carboplatin in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-BTOG2-LU3005, EU-20510, NCT00112710
9.	Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: WJTOG0101, NCT00139971
10.	Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEFCAPI O2, NCT00126269
11.	Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: B9E-MC-S062, AB 22/00, NCT00146276
12.	Phase III Randomized Study of Gemcitabine Hydrochloride With Versus Without Cisplatin in Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Phase: Phase III Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: CRUK-ABC-02, EU-205103, ISRCTN82956140, EUDRACT-2004-004882-14, CTA-21266/0005/001, NCT00262769
13.	Random Trial for Elderly Patients With NSCLC Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: INJE05-06, NCT00265694
14.	Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: tasmc-05-na-05160-ctil, NCT00295035
15.	Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) Phase: Phase III Type: Treatment Status: Active Age: 75 to 90 Sponsor: Other Protocol IDs: IFCT-0501, NCT00298415
16.	IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2005.386, NCT00300586
17.	Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1505, E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
18.	Phase III Study of Two Different Schedules (Weekly and Tri-Weekly) of Combination of Gemcitabine and Two Taxanes in MBC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9846, B9E-IT-S376, NCT00236899
19.	Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2004-09-027, NCT00329472
20.	A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HKNPCSG 0502, NCT00370890
21.	Phase III Randomized Study of Six Different Neoadjuvant Chemotherapy Regimens With or Without Neoadjuvant and Adjuvant Bevacizumab in Women With Operable Stage I-IIIA Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-B-40, NCT00408408
22.	Phase III Randomized Study of Chemoimmunotherapy Comprising Gemcitabine Hydrochloride and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
23.	Phase III Randomized Study of Intravesical Gemcitabine Hydrochloride Immediately After Transurethral Resection of the Bladder Tumor in Patients With Newly Diagnosed or Recurrent Superficial Transitional Cell Bladder Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0337, S0337, NCT00445601
24.	A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVF4095g, NCT00434642
25.	Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 3104000, NCT00437307